Home / Market News / $AGL
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Deutsche Bank Trims Price Target on agilon health to $132 From $139

Nov 18, 2026, 2:05 PM UTC · Primary ticker $AGL

Deutsche Bank has reduced its price target for agilon health from $139 to $132, while maintaining a 'Buy' rating. This indicates a slightly less optimistic outlook on the stock's future valuation, though the underlying positive sentiment remains.

Deutsche Bank has lowered its price target for agilon health (AGL) from $139 to $132. This adjustment reflects a revised valuation by the analyst, likely due to updated financial models or market conditions specific to the healthcare services sector. While the price target reduction is a negative signal for potential upside, the maintained 'Buy' rating suggests the firm still sees value in the company. For traders, this could lead to short-term downward pressure on AGL's stock as some investors might react to the lower target, but the long-term outlook, as per Deutsche Bank, remains positive. The key risk is if other analysts follow suit with similar downgrades, creating a broader negative sentiment.

$AGL negative Price target reduction
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.